UNSPSC 51432315: Olmesartan medoxomil

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C29H30N6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6M97XTV3HD, chemically known as 1h-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2-(1h-tetrazol-5-yl) (1,1-biphenyl)-4-yl)methyl)- but more generally known as olmesartan, which bears US NIH Compound Identifier 158781. European Medicines Agency schedules Olmesartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20707.

UNSPSC 51432315 Olmesartan medoxomil, a Commodity code, nominally covers a single antihypertensive drug product, but state and local procurement activity under this code spans broader pharmaceutical supply — specifically generic and branded medications, over-the-counter products, and emergency-use drugs procured by fire rescue services, state health agencies, and multistate cooperative purchasing alliances. State and local governments buy finished pharmaceutical products through this code to stock emergency medical services, pharmacy benefit programs, and government employee health plans. Issuing bodies include municipal fire rescue departments (Tampa Fire Rescue via the City of Tampa), state health agencies (Texas Health and Human Services Commission), and multistate purchasing cooperatives administering joint procurement for participating state and local members (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Solicitations follow the full range of state and local notice types — sealed competitive bids, RFIs for exploratory market intelligence, and formal RFPs for volume supply agreements.

Recent activity clusters in the South and Upper Midwest. Tampa's City of Tampa Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for advanced life support medications including epinephrine, labetalol, adenosine, and diltiazem — medications outside the nominal olmesartan scope but typical of what fire rescue services actually procure; the contract carried an estimated value of $40,000 with a one-year term and optional renewals, and applied a 5 percent SLBE bid discount. Texas HHS Commission posted an RFI in March 2026 to explore direct-to-manufacturer prescription fulfillment models, signaling interest in pharmacy benefit restructuring but not yet a commodity-specific opportunity. MMCAP, administered by the Minnesota Department of Administration, issued a multistate RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to flow through three authorized national wholesalers, effective July 1, 2026, with a two-year initial term and incumbent contract extensions through June 30, 2028; MMCAP's evaluation weighted price competitiveness at 75 percent and required vendors to maintain relationships with at least two of three named wholesalers and comply with cGMP and DSCSA standards.